# A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

> **NCT00936650** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 78 (actual)

## Conditions studied

- Hyperparathyroidism, Primary

## Interventions

- **DRUG:** placebo
- **DRUG:** cinacalcet

## Key facts

- **NCT ID:** NCT00936650
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2001-03
- **Final completion:** 2001-06
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2013-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00936650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00936650, "A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00936650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*